Popular terms

G Proteins topics
G Proteins
Antibodies
Immunoglobulin
Metalloprotein
Chemotherapeutic Agent
Kinase Inhibitor
Tetrapeptide
Apoptosis Protein
Topoisomerase
Peptidomimetic
Fractionation
Medical Treatment
Chromatograph
Encapsulation
Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Proteins patents

      

This page is updated frequently with new G Proteins-related patent applications.




Date/App# patent app List of recent G Proteins-related patents
08/18/16
20160238615 
 Solid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip patent thumbnailSolid phase extraction of global peptides, glycopeptides, and glycans using chemical immobilization in a pipette tip
Pipette tips comprising aldehyde-reactive or amino-reactive chemical moieties or other chemical moieties capable of conjugating to one or more reactive groups of amino acid side chains or protein modifications and methods for preparing the tips are provided. In addition, a high throughput method for identifying proteins, glycoproteins, and glycans in a plurality of samples using the pipette tips is also provided..
The Johns Hopkins University


08/18/16
20160238602 
 Method for detecting proteins by means of aptamers patent thumbnailMethod for detecting proteins by means of aptamers
The present invention describes a method for an in vitro detection of a first protein in a sample, comprising the steps of: a) separating the sample by means of a native separation method; b) transferring the separated sample onto a membrane; c) contacting the membrane with an aptamer which specifically binds to the first protein; and d) detecting the first protein by detecting the aptamer bound to the first protein.. .
Technische Universität Berlin


08/18/16
20160238600 
 Method for selecting a single cell expressing a heterogeneous combination of antibodies patent thumbnailMethod for selecting a single cell expressing a heterogeneous combination of antibodies
Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing..
Merus B.v.


08/18/16
20160237469 
 Microbial analysis patent thumbnailMicrobial analysis
The present invention is concerned with a method of identifying microbial strains (e.g. From a cell culture), the method comprising; i) a lipid extraction step, comprising extraction of phospholipids from the microbe, suitably with an extraction composition comprising more than 50 vol % meoh; ii) a sample preparation step, comprising preparation of a maldi sample incorporating the extracted lipids; iii) a data gathering step, comprising performing maldi-based mass spectrometry on the maldi sample, and iv) a microbe identification step, comprising analysis of the mass spectrometry data to characterise or identify the microbial strain.
Kratos Analytical Limited


08/18/16
20160237423 
 Methods for the selection of binding proteins patent thumbnailMethods for the selection of binding proteins
This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mrna display and yeast surface display in a way that takes advantage of the desirable attributes of both processes..
Bristol-myers Squibb Company


08/18/16
20160237142 
 Synthetic single domain antibody patent thumbnailSynthetic single domain antibody
The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d ab) and its use in generating synthetic single domain antibody library (hs2d ab-l1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics..
Centre National De La Recherche Scientifique - Cnrs


08/18/16
20160235833 
 Chimeric factor h binding proteins (fhbp) and methods of use patent thumbnailChimeric factor h binding proteins (fhbp) and methods of use
Chimeric fhbps that can elicit antibodies that are bactericidal for different fhbp variant strains of n. Meningitidis, and methods of use, are provided..
Children's Hospital & Research Center Oakland


08/11/16
20160230205 
 Activated formylglycine-generating enzymes and methods of producing and using the same patent thumbnailActivated formylglycine-generating enzymes and methods of producing and using the same
The present disclosure provides activated formylglycine-generating enzymes (fge), methods of producing activated fge, and their use in methods of producing a protein comprising a formylglycine (fgly) residue. The methods of producing activated fge, as well as methods of use of activated fge in producing fgly-containing proteins, include both cell-based and cell-free methods.
R.p. Scherer Technologies, Llc


08/11/16
20160229910 
 Tm4sf1 binding proteins and methods of using same patent thumbnailTm4sf1 binding proteins and methods of using same
This present invention relates to compounds (e.g., tm4sf1 binding proteins, e.g., anti-tm4sf1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of seq id no: 1. In particular, the compounds of the invention are capable of being internalized into a tm4sf1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of seq id no: 1.
Beth Israel Deaconess Medical Center, Inc.


08/11/16
20160229906 
 Mice that produce antigen-binding proteins with ph-dependent binding characteristics patent thumbnailMice that produce antigen-binding proteins with ph-dependent binding characteristics
Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided.
Regeneron Pharmaceuticals, Inc.


08/04/16
20160223561 

Methods and kits for isolation and analysis of a chromatin region


The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas


08/04/16
20160222364 

Modified zinc finger binding proteins


Disclosed herein are compositions and method comprising non-canonical (e.g., non-c2h2) zinc finger proteins.. .
Sangamo Biosciences, Inc.


08/04/16
20160222112 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222111 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222110 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222109 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160222108 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


08/04/16
20160220649 

Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases


On the basis thereof, the authors of the present invention have combined a peptide, a protein or a polypeptide associated with a “conformational disease” with a biologically active or functional hsp, resulting in a different immunoactive complex which is advantageous for treating the “conformational disease” in question associated with the peptide, protein or polypeptide used.. .

08/04/16
20160220610 

Pharmaceutical or nutraceutical composition


The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions.

08/04/16
20160219847 

Common light chain mouse


A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.


07/28/16
20160215059 

Icos binding proteins


The present invention relates to an icos binding protein, or antigen binding portion thereof that is an agonist human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited


07/28/16
20160215028 

Biomarkers for mycobacterium avium paratuberculosis (map)


Described are methods and products useful for identifying subjects with mycobacterium avium subspecies paratuberculosis (map). A number of protein antigens secreted into culture filtrate by map are identified and binding proteins selective for these antigens are demonstrated to be useful for detecting subjects with map infections including subjects with johne's disease..
University Of Guelph


07/28/16
20160213632 

Memory performance and prevention and treatment of neurodegenerative diseases


The present technology relates to improvement of memory performance and the prevention or treatment of brain disorders associated with memory loss. In particular, the invention relates to the use of centaurin-α1 (centa1), centa1 activating proteins, and centa1 effector proteins as therapeutic targets to improve memory and cognitive performance in a normal subject and/or in a subject with neurological disorders associated with memory and/or cognitive impairments, such as alzheimer's disease..
Max Planck Florida Institute For Neuroscience


07/21/16
20160208274 

Blood clot-dissolving proteins produced in seeds


Transgenic plants in which blood-clot dissolving proteins are produced in seeds of the plants are provided. Expression of the proteins is driven by a seed specific or selective promoter.
Northeastern State University


07/21/16
20160207962 

Electron spin labeled ice binding compounds used for carrying paramagnetic centers for dynamic nuclear polarization


Spin labeled ice binding compounds (ibcs) including ice binding proteins (ibps), also called antifreeze proteins (afps) and their analogs are exploited to carry the paramagnetic centers for dynamic nuclear polarization (dnp), for enhancing nuclear magnetic resonance (nmr) signal intensities. Use of spin labeled ibcs to perform dnp exploits the ibcs' ability to homogeneously distribute the paramagnetic centers in frozen water solution at low temperature, leading to high dnp efficiency.
The Trustees Of California State University


07/14/16
20160202234 

Method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation


The invention relates to a method for evaluating, via biodosimetry, the irradiation dose received by a person subjected to ionizing radiation. Said method comprises: a) sampling, in at least one area of the body of the person, the follicles or bulbs of head and/or body hair of the person; b) extracting proteins from cells of said sampled hair bulbs or follicles, wherein said proteins, including proteins from the atm system, are subjected to phosphorylation and/or acetylation induced by ionizing radiation; and c) analyzing at least two types of extracted proteins and interpreting the analysis results in order to determine the irradiation dose in the or each sampling area..
Acubens


07/14/16
20160201031 

Composition and methods for culturing cells


The present disclosure provides compositions for in vitro culture of cells. The present disclosure provides methods for in vitro culture of cells.
The Regents Of The University Of California


07/14/16
20160200847 

Clickable polymers and gels for microarray and other applications


Fabrication of arrays, including glycan arrays, that combines the higher sensitivity of a layered si—sio2 substrate with novel immobilization chemistry via a “click” reaction. The novel immobilization approach allows the oriented attachment of glycans on a “clickable” polymeric coating.

07/14/16
20160200823 

Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof


This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a cd154 (cd40l) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized fab fragment comprising a variable heavy chain sequence according to seq id no: 1 and comprising a variable light chain sequence according to seq id no: 2 specifically binds.
Biogen Idec Ma Inc.


07/14/16
20160200813 

Lrp-8 binding proteins


The disclosure provides binding proteins that specifically bind to lrp-8 and optionally cross the blood brain barrier (bbb), localize to the brain and/or localize to the spinal cord.. .
Abbvie Inc.


07/14/16
20160200811 

Dual variable region antibody-like binding proteins having cross-over binding region orientation


The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins..
Sanofi


07/14/16
20160199443 

Polypeptide targeting to mitochondria


Methods for delivering non-mitochondrial proteins to mitochondria are provided. Also provided are nucleic acid constructs comprising a coding sequence encoding a dna-binding polypeptide, fused to a mitochondrial targeting sequence (mts) and a nuclear export signal (nes), and the encoded proteins.
Medical Research Council


07/14/16
20160198737 

Method for recovering proteins from waste water discharged during process of producing fish meat processed product


According to the present invention, a method for recovering useful fish meat proteins from waste water generated during fish paste or fishmeal production is provided. The provided is a method for recovering water-soluble proteins from fish paste leaching waste water or stick water, comprising: adjusting the ph of fish paste leaching waste water or stick water to 4.5-5.5 to insolubilize water-soluble proteins; heating the insolubilized proteins to 30° c.
Maruha Nichiro Corporation


07/07/16
20160195525 

Diagnosis and treatment of mycobacteria infections


The invention provides isolated, purified, recombinant receptor binding proteins gp-6, gp-10 and gp-31 from mycobacterium phage l5, and methods for producing these recombinant receptor binding proteins. The invention also provides the use of recombinant receptor binding proteins, including gp-6, gp-10 and gp-31, as probes for the identification and diagnosis of mycobacterium infections and conditions caused by mycobacterium.
The Governors Of The University Of Alberta


07/07/16
20160194606 

Methods for inducing the differentiation of blood monocytes into functional dendritic cells


Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood and produce a leukocyte concentrate comprising monocytes and plasma containing proteins.
Yale University


07/07/16
20160194409 

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


07/07/16
20160194397 

Fc receptor binding proteins


This disclosure provides, inter alia, proteins that bind to fcrn, e.g., immunoglobulins that inhibit fcrn with high affinity and selectivity. The fcrn-binding proteins can be used to treat a variety of disorders including autoimmune disorders..
Biogen Hemophilia Inc.


07/07/16
20160193358 

Antigen binding proteins


The present invention concerns antigen binding proteins and fragments thereof which specifically bind b cell maturation antigen (bcma), particularly human bcma (hbcma) and which inhibit the binding of baff and april to the bcma receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods..
Glaxo Group Limited


07/07/16
20160193150 

Reducing or non-reducing polynucleotide polymer for drug delivery and preparing same


The present invention relates to a reducing or non-reducing polynucleotide polymer for drug delivery and a method for preparing same, and provides a reducing or non-reducing polymer synthesized by using nucleotides, a method for preparing same, and a polymer composition for drug delivery containing the reducing or non-reducing polymer. The present invention relates to a drug delivery carrier for delivering proteins or peptides to a targeted area through electrostatic attraction, by obtaining a negatively (−) charged polymer by using nucleotides to synthesize the reducing or non-reducing polymer, which is easily breakable due to disulfide bonds, and then bonding the negatively (−) charged polymer with a positively (+) charged protein or peptide, wherein a polymer derived from a non-viral drug delivery carrier containing the novel reducing or non-reducing polymer is capable of effectively enabling escape of a drug, delivered by means of proton buffering activity, from an endosome to other organelles in a cell..
Utah-inha Dds & Advanced Therapeutics Research Center


07/07/16
20160192697 

Protein-enriched tobacco-derived composition


The present disclosure describes methods of obtaining and/or deriving proteins from plants of the nicotiana species and methods for incorporation of such proteins into various products. For example, a method for obtaining a protein-enriched material from a plant of the nicotiana species or portion thereof is provided, comprising: extracting one or more proteins from the plant material into a solvent to form a liquid protein-containing extract; separating a solid extracted plant material from the liquid protein-containing extract; clarifying the liquid protein-containing extract to form a clarified protein-containing extract and a solids fraction; and treating the clarified protein-containing extract so as to provide a protein-enriched material comprising at least about 60% protein by weight..
R.j. Reynolds Tobacco Company


06/30/16
20160187357 

Compositions and methods for increasing bone mineralization


A novel class or family of tgf-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules..

06/30/16
20160186157 

Intein-modified enzymes, their production and industrial application


A method of predicting an intein insertion site in a protein that will lead to a switching phenotype is provided. The method includes identifying a plurality of c/t/s sites within the protein; selecting from the plurality of c/t/s/sites those that are ranked 0.75 or higher by a support vector machine, within ten angstroms of the active site of the protein, and at or near a loop-β-sheet junction or a loop-α-helix junction.

06/30/16
20160184413 

Formulation for stabilizing proteins, which is free of mammalian excipient


The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, wherein the formulation is free of stabilising proteins.. .

06/23/16
20160177300 

Means and methods for the generation of mammalian producer cells for the production of recombinant proteins


The present invention relates to the generation of mammalian cells capable of producing proteins at an industrial scale and means and methods to obtain and use said cells, in particular for protein production.. .

06/23/16
20160176971 

Methods and compositions relating to anti-il-21 receptor antibodies


The present invention provides compositions and methods relating to antigen binding proteins against il-21 receptor.. .

06/23/16
20160176958 

Tnf-alpha binding proteins


Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (tnf-α), e.g., human tnf-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies..

06/16/16
20160168593 

Methods and compositions for enhancing targeted transgene integration


Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of r loop formation or inhibitors of r-loop repair and/or one or more up-regulators of the tc-ner pathway to the target cell.. .
Sangamo Biosciences, Inc.


06/16/16
20160168559 

Biocatalytical composition


The present invention relates to means and methods for protecting proteins and protein-type compounds in industrial and other applications. In particular, the invention provides a composition comprising at least one protein or protein-type compound immobilized at the surface of a solid carrier embedded in a protective material.
Inofea Gmbh


06/16/16
20160168264 

Antibodies directed to her-3 and uses thereof


The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Amgen, Inc.


06/16/16
20160168205 

Methods and compositions for labeling polypeptides


Synthesis of many proteins is tightly controlled at the level of translation and plays an essential role in fundamental processes such as cell growth and proliferation, signaling, differentiation or death. Methods that allow imaging and identification of nascent proteins allow for dissecting regulation of translation, both spatially and temporally, including in whole organisms.
President And Fellows Of Harvard College


06/16/16
20160168194 

Chromatography matrices including novel staphylococcus aureus protein a based ligands


The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation


06/16/16
20160168154 

Inhibitors of transcription factors and uses thereof


The present invention provides novel compounds of any one of formulae (i) to (iv), and pharmaceutically compositions thereof. Compounds of any one of formulae (i) to (iv) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (bets)).
University Of Massachusetts


06/16/16
20160166663 

Vaccine formulations that induce a th2 immune response


The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.


06/09/16
20160160268 

Amdinocillin for rapid determination of susceptibility to beta-lactam antibiotics


Described are methods for detecting susceptibility of a specimen to antibiotics, and particularly for enhancing such susceptibility testing for beta lactam antibiotics and antibiotics that bind to penicillin-binding proteins. The method comprises contacting the specimen with an oligonucleotide probe that specifically hybridizes with a target nucleic acid sequence region of ribosomal rna.
United States Government Represented By The Department Of Veterans Affairs


06/09/16
20160160048 

Polymers and plastics derived from animal proteins


The invention is directed to a method for preparing a polymer derived from an animal protein, such as in a feedstock derived from animal by-products. The method involves hydrolyzing proteins present in a feedstock to obtain hydrolyzed proteins, wherein hydrolysis is conducted under conditions sufficient to digest the proteins and destroy pathogens; extracting a protein fraction from the hydrolyzed proteins; and treating the protein fraction with a crosslinking reagent to form the polymer.
The Governors Of The University Of Alberta


06/09/16
20160159923 

Antibodies to matrix metalloproteinase 9


The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


06/09/16
20160159865 

Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof


Non-naturally occurring factor h binding proteins derived from variant 3 fhbp that can elicit antibodies that are bactericidal for at least one strain of n. Meningitidis, and methods of use of such proteins, are provided.
Children's Hospital & Research Center Oakland


06/09/16
20160159856 

Affinity tags and processes for purifying and immobilizing proteins using same


The present disclosure provides affinity tags, fusion proteins comprising one or more affinity tags, compositions comprising a fusion protein, methods of purifying a protein using an affinity tag, and devices for purifying a protein using an affinity tag.. .
University Of Washington Through Its Center For Commercialization


06/02/16
20160153911 

Instant view of protein bands


Apparatus, reagents, pre-treated proteins and methods for dying proteins in electrophoresis run gels, and for instantly viewing such dyed protein samples in an electrophoresis gel. A protein mixing solution containing a fluorescence dye is mixed with a protein sample so that fluorescence dyes within the protein mixing solution conjugate to proteins within the protein sample.

06/02/16
20160153872 

System and retrieval treatment of proteins in formalin-fixed paraffin-embedded tissue section


A protein retrieval treatment system used for activating proteins contained in a deparaffinized tissue section obtained by removing paraffin from a formalin-fixed paraffinembedded tissue section. The protein retrieval treatment system includes: a dispensing unit for dispensing a retrieval treatment solution over a dispensing area including a measurement area on the deparaffinized tissue section; and a moist-heat treatment unit for heating, in a saturated water vapor, the deparaffinized tissue section with the dispensing area covered with the retrieval treatment solution..
Shizuoka Prefecture


06/02/16
20160152728 

Antibody binding sites specific for egfrviii


This application describes binding proteins that specifically bind to egfrviii and multispecific binding proteins that specifically bind to egfrviii and cd3. Further described is a multispecific tandem diabody that binds to egfrviii and cd3.
Affimed Gmbh


06/02/16
20160152725 

Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide


Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv (scfv) fragments, as well as chimeric antigen receptors.
Memorial Sloan-kettering Cancer Center


06/02/16
20160152700 

Antigen binding proteins capable of binding thymic stromal lymphopoietin


The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (tslp), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-tslp antibodies and derivatives of such antibodies.
Amgen Inc.


05/26/16
20160147936 

Rational solubilising proteins


A method and data processing system for identifying mutations or insertions that alter a property such as the solubility or aggregation propensity of an input polypeptide chain. The method comprises inputting a sequence of amino acids and a structure for said sequence for said target polypeptide chain; calculating a structurally corrected solubility or aggregation propensity profile for said target polypeptide chain; selecting, using said calculated profile, regions within said target polypeptide chain; identifying at least one position within each selected region suitable for mutations or insertions; generating a plurality of mutated sequences by mutations or insertions at least one identified position; and predicting a value of the solubility or aggregation propensity for each of the plurality of mutated sequences whereby any alteration to the solubility or aggregation propensity of the input polypeptide chain is identified.
Cambridge Enterprise Limited


05/26/16
20160146828 

Chemistry, systems and methods of translocation of a polymer through a nanopore


Embodiments disclosed herein are directed to recognition tunneling systems, methods and devices, and more particularly, to chemical reactions for selectively labeling proteins and peptides and placing protein and/or peptides into, or onto a nanopore formed in a solid support and threading such in and/or through the nanopore, with such nanopores, in some embodiments, including a molecular motor to pull or otherwise force the protein/peptide through the nanopore.. .
Arizona Board Of Regents Acting For And On Behalf Of Arizona State University


05/26/16
20160146827 

Genetically encoded sensors for imaging proteins and their complexes


Isolated truncated and mutated sensor proteins derived from flavoproteins that are 12-20 kda or less, genetically encoded for detection and imaging of protein complexes having long fluorescent lifetimes that can be 4.0 ns or greater.. .
President And Board Of Trustees Of Santa Clara College


05/26/16
20160145351 

Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof


The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Amgen Inc.


05/26/16
20160145333 

Cb-1 receptor antigen-binding proteins and uses thereof


This disclosure relates to cb1 receptor antigen-binding proteins, e.g. Antibodies and methods of using the cb1 receptor antibodies.
Amgen Inc.


05/26/16
20160145332 

Il-21 binding proteins and uses thereof


The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (il-21) and uses thereof, e.g., in therapy.. .
Monash University


05/26/16
20160145322 

Human antibodies binding to rsv g proteins


The disclosure provides isolated antibodies and antigen-binding fragments that bind to the g protein of rsv and which are capable of neutralizing rsv.. .
Crucell Holland B. V.


05/19/16
20160138034 

Novel genes involved in biosynthesis


The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited


05/19/16
20160137739 

Oncostatin m receptor antigen binding proteins


The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Biogen Ma Inc.


05/19/16
20160137708 

Il-1 family variants


The present invention provides compositions and methods relating to il-1rrp2 requiring proteins.. .
Amgen Inc.


05/19/16
20160136239 

Method for producing autologous proteins


A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
Arthrogen Gmbh


05/12/16
20160132634 

Computer-implemented methods of determining protein viscosity


The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag


05/12/16
20160130568 

Thermophilic and thermoacidophilic glycosylation genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods


Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for glycosylating and/or post-translationally modifying proteins using isolated and/or purified polypeptides and nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc.


05/12/16
20160130332 

Antibodies to human signal peptide-containing proteins


The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


05/12/16
20160130327 

Cmv neutralizing antigen binding proteins


The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (cmv). Also encompassed by the invention are antigen binding proteins that have been humanized.
Board Of Regents Of The University Of Texas System


05/05/16
20160123956 

Modified membrane spanning proteins and methods for the preparation and use thereof


In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like.
Abilita Bio, Inc.


05/05/16
20160122439 

Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof


Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant dll4 and/or vegf expression or activity.. .
Abbvie Inc.


05/05/16
20160122437 

Antibodies to matrix metalloproteinase 9


The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


04/28/16
20160115210 

Colorimetric and fluorescent proteins


The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.. .
Board Of Trustees Of Michigan State University


04/21/16
20160109424 

Swath™ data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products


Systems and methods are provided for detecting host cell contaminants in a protein biotherapeutic product using sequential windowed acquisition tandem mass spectrometry. Sequential windowed acquisition is performed on a protein biotherapeutic product sample by sequentially stepping a precursor mass window across a mass range, fragmenting transmitted precursor ions of each stepped precursor mass window, and analyzing product ions produced from the fragmented transmitted precursor ions.

04/21/16
20160106850 

Methods and compositions for wound treatment


The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .

04/14/16
20160102150 

Plasma kallikrein binding proteins


Plasma kallikrein binding proteins and methods of using such proteins are described.. .

04/07/16
20160097053 

Yeast promoters from pichia pastoris


In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences


04/07/16
20160097050 

Devices and methods for display of encoded peptides, polypeptides, and proteins on dna


A novel method for displaying proteins and peptides is disclosed in which individual proteins or peptides remain associated with the dna encoding them. Proteins or peptides can be generated by in vitro translation of dna templates, either free in solution or arrayed on a solid support, such that the proteins or peptides remain immobilized on their dna templates.
The Board Of Trustees Of The Leland


04/07/16
20160095917 

Dps fusion proteins for use in vaccines and diagnostics


Novel nanoparticle fusion proteins comprising proteins or peptides fused to dps (dna binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.. .
Kj Biosciences Llc


04/07/16
20160095313 

Antimicrobial compositions and methods


The present invention is generally related to a product and process to reduce the microbial contamination on organic matter, such as processed meat, fruits and vegetables, plant parts, inanimate surfaces such as textiles and stainless steel, and in the mouth or on dental products. In particular, the invention is related to a product and process to disinfect surfaces using an antimicrobial composition containing an antimicrobial lipid, an enhancer selected from the group consisting of bacteriocins, antimicrobial enzymes, sugars, sugar alcohols, iron-binding proteins and derivatives thereof, siderophores, and combinations thereof, and optionally a surfactant..
3m Innovative Properties Company


03/31/16
20160090414 

Binding proteins specific for insulin-like growth factors and uses thereof


Binding proteins, such as antibodies directed to igf-ii with cross-reactivity to igf-i and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the igf-ii with cross-reactivity to igf-i are disclosed.
Medimmune Limited


03/31/16
20160090404 

Modified biotin-binding protein, fusion proteins thereof and applications


The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen.
Children's Medical Center Corporation


03/31/16
20160089445 

Derivatisation of biological molecules


The polymers are particularly suitable for derivatising proteins, such as interferon-α.. .

03/24/16
20160082083 

Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity


Insulin-like growth factor binding proteins (igfbps) and variants thereof, including igfbp-1, igfbp-2, igfbp-3, igfbp-4, igfbp-5, igfbp-8 and the c-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin b activity.. .
National Research Council Of Canada




G Proteins topics: G Proteins, Antibodies, Immunoglobulin, Metalloprotein, Chemotherapeutic Agent, Kinase Inhibitor, Tetrapeptide, Apoptosis Protein, Topoisomerase, Peptidomimetic, Fractionation, Medical Treatment, Chromatograph, Encapsulation, Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.2572

4685

3 - 0 - 101